Abigail Brooks, MA

Marla Dubinsky, MD, discusses the use of segmental intestinal ultrasound to address screen failure associated with the SES-CD in clinical trials and for detecting transmural healing.

The analysis of several oral antidiabetic drugs revealed patients taking SGLT2 inhibitors had more NAFLD regression and fewer adverse liver-related outcomes.

The decision makes budesonide oral suspension (Eohilia) the first and only FDA-approved oral therapy for patients ≥ 11 years of age with eosinophilic esophagitis.

Findings suggest the risk of hepatocellular carcinoma may persist in patients with HCV, even after achieving SVR with direct-acting antiviral therapy.

A distinctive gene expression profile was identified in patients with IgA nephropathy using NanoString mRNA technology, suggesting inflammatory and fibrotic targets in the disease.

Patients who switched from originator adalimumab to a biosimilar experienced more treatment-emergent adverse events compared to those who stuck with the biosimilar or the reference drug.

HCV seroprevalence and antigen positivity were both low, suggesting universal birth cohort screening may not be necessary or cost-effective.

Stephen Harrison, MD, provides insight into the use of resmetirom for NASH with fibrosis ahead of the thyroid hormone receptor-β selective agonist’s March 14 PDUFA date.

Our January 2024 month-in-review spotlights some of our top coverage in nephrology, ranging from FDA news to clinical trial data and research about approaches to improving renal health.

Stephen Harrison, MD, discusses results from the phase 3 MAESTRO-NASH trial, highlighting resmetirom’s safety and efficacy for NASH resolution and fibrosis improvement.

Findings from this retrospective study help address challenges in distinguishing immunoglobulin A nephropathy from immunoglobulin A vasculitis-associated nephritis, overcoming their shared pathogenetic features.

Findings highlight the potential benefits of implementing home-based screening for albuminuria in the general population to reduce the burden of kidney and cardiovascular diseases while maintaining cost-effectiveness.

Results of the systematic review and meta-analysis support the use of pan-genotypic DAA regimens for the treatment of chronic HCV in adolescents and children ≥ 3 years of age.

Hydroxychloroquine and leflunomide were found to be safe and effective for treating IgAN, with study results showing the use of both immunosuppressants in combination with a renin-angiotensin system inhibitor proved most effective in improving proteinuria and stabilizing renal function.

The literature review discusses the rising incidence of eosinophilic esophagitis, highlighting the efficacy of proton pump inhibitors, challenges in diagnosis, and the need for collaborative decision-making in its management.

The editorial team’s monthly recap of the top news in hepatology features research emphasizing women’s health in liver disease, a look at some less-recognized health benefits associated with achieving SVR, and promising approaches for preventing and treating hepatic conditions.

Study results called attention to the negative impact of living in a rural residence and a highly dependent neighborhood on HCV screening by 2 years of age in children born to HCV RNA positive mothers.

Obesity was linked to an increased risk of focal segmental glomerulosclerosis and hypertensive nephropathy, with further analysis revealing its impact on the risk of developing end-stage kidney disease.

Following the January 25, 2024 approval of dupilumab for eosinophilic esophagitis in patients 1-11 years of age, a trio of pediatric gastroenterologists shares their thoughts on the new indication, their anticipated priority of use, and potential hurdles to optimal treatment uptake.

Our January 2024 Month in Review spotlights the FDA approval of a new indication of dupilumab (Dupixent) for pediatric eosinophilic esophagitis, new clinical trial data, and research about the prevention and management of IBD.

A high intake of fish and vegetables at 1 year of age was associated with a lower risk of IBD, while consuming sugar-sweetened beverages was linked to a greater risk of developing IBD.

Low eGFRcr-cys was more strongly and uniformly associated with adverse outcomes compared to low eGFRcr in an older patient population, highlighting the benefit of including cystatin C in GFR estimation.

Vitiligo was significantly associated with an increased risk of bacteremia, cellulitis, and herpes zoster and was more common among those with female sex, Black compared to White race, Hispanic ethnicity, hepatitis C infection, and tobacco use.

Although there was a greater prevalence of ALD and MetALD among male study participants, females had a greater risk of mortality from both SLD phenotypes, highlighting a potentially greater impact of alcohol consumption on women with liver disease than men.

Compared to glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors, Use of sodium-glucose cotransporter 2 inhibitors was linked to a decreased risk of nephrolithiasis in patients with type 2 diabetes.

Results showed treatment with dapagliflozin 10 mg was associated with clinically meaningful attenuations in eGFR slope in patients with CKD and urinary albumin-to-creatinine ratio < 200 mg/g.

More than half of patients received return-IBD care via telehealth in the post-COVID period, and those with longer drive times were more likely to continue telehealth care.

Use of the electronic AKI alert system led to slight improvements in intervention rates and AKI diagnosis, although kidney function and patient-centered outcomes did not differ from patients receiving usual care.

Results showed a 12% incidence of HCV in pregnancy with a preterm birth rate nearly double the national average, although no statistically significant difference in preterm birth rates was observed between HCV-positive and HCV-negative patients.

We sat down with Evan Dellon, MD, MPH, to discuss the use of dupilumab in pediatric EoE patients, with the agent gaining FDA approval as the first and only indication for this patient population on January 25, 2024.